Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors. (Q33438326)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28076709%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

title

Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28076709%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

main subject

phase III clinical trial

0 references

author

Ettore Seregni

27

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28076709%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Thomas O'Dorisio

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28076709%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Thomas Thevenet

31

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28076709%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

34

Dik Kwekkeboom

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28076709%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

35

Eric Krenning

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28076709%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

author name string

Jonathan Strosberg

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28076709%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Ghassan El-Haddad

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28076709%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Edward Wolin

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28076709%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Andrew Hendifar

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28076709%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

James Yao

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28076709%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Beth Chasen

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28076709%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Erik Mittra

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28076709%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Pamela L Kunz

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28076709%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Matthew H Kulke

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28076709%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Heather Jacene

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28076709%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Richard P Baum

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28076709%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Harshad R Kulkarni

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28076709%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Martyn Caplin

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28076709%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Rachida Lebtahi

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28076709%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Timothy Hobday

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28076709%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Ebrahim Delpassand

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28076709%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Al Benson

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28076709%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Rajaventhan Srirajaskanthan

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28076709%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Marianne Pavel

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28076709%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Jaime Mora

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28076709%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Jordan Berlin

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28076709%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Enrique Grande

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28076709%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Nicholas Reed

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28076709%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Kjell Öberg

28

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28076709%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Maribel Lopera Sierra

29

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28076709%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Paola Santoro

30

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28076709%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Jack L Erion

32

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28076709%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Philippe Ruszniewski

33

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28076709%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

NETTER-1 Trial Investigators

36

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28076709%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

David Bushnell

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28076709%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Eric Van Cutsem

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28076709%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

language of work or name

English

0 references

publication date

1 January 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28076709%20AND%20SRC:MED&resulttype=core&format=json

The New England Journal of Medicine

9 April 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28076709%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

volume

376

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28076709%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

page(s)

125-135

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28076709%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28076709%20AND%20SRC:MED&resulttype=core&format=json

Nephrotoxicity after PRRT with (177)Lu-DOTA-octreotate

9 April 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5895095

Radiolabeled Somatostatin Analogue Therapy Of Gastroenteropancreatic Cancer

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5895095

Effectiveness and side-effects of peptide receptor radionuclide therapy for neuroendocrine neoplasms in Germany: A multi-institutional registry study with prospective follow-up

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5895095

ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5895095

Lanreotide in metastatic enteropancreatic neuroendocrine tumors

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5895095

Long-term hematotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5895095

Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5895095

Peptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTATATE: the IEO phase I-II study

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5895095

Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5895095

One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5895095

A 5-decade analysis of 13,715 carcinoid tumors

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5895095

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5895095

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5895095

Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5895095

Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5895095

Subacute haematotoxicity after PRRT with (177)Lu-DOTA-octreotate: prognostic factors, incidence and course

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5895095

Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5895095

GEPNETs update: Radionuclide therapy in neuroendocrine tumors

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5895095

Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: the first US phase 2 experience.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5895095

Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced grade 1/2 pancreatic neuroendocrine tumours

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5895095

Prognostic validity of the American Joint Committee on Cancer staging classification for midgut neuroendocrine tumors

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5895095

Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5895095

Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5895095

Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5895095

Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5895095

Radiotherapy with a radiolabeled somatostatin analogue, [111In-DTPA-D-Phe1]-octreotide. A case history

31 October 2018

1 reference

12 December 2020

Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy

1 reference

12 December 2020

Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon

1 reference

12 December 2020

Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue

1 reference

12 December 2020

The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors

1 reference

12 December 2020

Identifiers

DOI

10.1056/NEJMOA1607427

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28076709%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28076709%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

1 reference